Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27

被引:43
|
作者
Montgomery, HE
Kiernan, LA
Whitworth, CE
Fleming, S
Unger, T
Gohlke, P
Mullins, JJ
McEwan, JR
机构
[1] UCL, Sch Med, Hatter Inst Cardiovasc Studies, London W1N 8AA, England
[2] Univ Edinburgh, Ctr Genome Res, Edinburgh, Midlothian, Scotland
[3] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland
[4] Univ Kiel, Inst Pharmacol, Kiel, Germany
关键词
renin-angiotensin system; malignant hypertension; transgenic rats;
D O I
10.1097/00004872-199816050-00011
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Activation of the renin-angiotensin system has been implicated strongly in the transition from benign to malignant hypertension. However, the concomitant rise in blood pressure might also have a direct effect on the vascular wall by initiating fibrinoid necrosis and myointimal proliferation, Ascertaining the relative importance of these two factors in this process has proved difficult. TGR(mREN2)27 heterozygotes (HanRen2/Edin--) have previously been shown to develop malignant hypertension spontaneously and exhibit the characteristic features of human malignant hypertension, Objective Tissue renin-angtiotensin systems have been implicated in the pathogenesis of malignant hypertension, We set out to determine whether inhibition of this system might protect against development of the disease in a rat model, Method Male TGR(mREN2)27 heterozygotes (n = 24) were given a non-hypotensive dose of the angiotensin converting enzyme inhibitor ramipril (5 mu g/kg per day) from 28 to 120 days of age, untreated rats acting as controls (n = 40), The incidences of malignant hypertension were compared. Systolic blood pressure was measured by tail-cuff plethysmography during treatment; tissue and plasma angiotensin converting enzyme levels and renal histological changes were assessed at the end of the treatment period or upon development of malignant hypertension. Results Sixty-three per cent of control rats and 4% of angiotensin converting enzyme inhibitor-treated rats had developed malignant hypertension by 120 days despite there having been no significant difference in systolic blood pressure throughout the course of treatment. Angiotensin converting enzyme activities in kidney, heart and resistance vessels, though not that in plasma, were significantly lower in the treated rats, The degree of medial wall thickening did not differ between the two groups whereas evidence of tissue injury (e.g. intimal fibrosis, fibrinoid necrosis and nephron injury) was significantly less common among rats in the angiotensin converting enzyme inhibitor-treated group, Conclusions Tissue angiotensin converting enzyme inhibition at a non-hypotensive dose almost completely prevented mortality from malignant hypertension and significantly reduced tissue injury in this model, implicating angiotensin II rather than high blood pressure as the principal 'vasculotoxic' agent in malignant hypertension, (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:635 / 643
页数:9
相关论文
共 50 条
  • [1] ROLE OF TISSUE RENIN IN THE PATHOPHYSIOLOGY OF HYPERTENSION IN TGR(MREN2)27 RATS
    BADER, M
    ZHAO, Y
    SANDER, M
    LEE, MA
    BACHMANN, J
    BOHM, M
    DJAVIDANI, B
    PETERS, J
    MULLINS, JJ
    GANTEN, D
    HYPERTENSION, 1992, 19 (06) : 681 - 686
  • [2] Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade
    Bohm, M
    Lippoldt, A
    Wienen, W
    Ganten, D
    Bader, M
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 1996, 164 : 217 - 221
  • [3] REGULATION OF ALDOSTERONE SECRETION AND ADRENAL RENIN IN TGR(MREN2)27
    PETERS, J
    DJAVIDANI, B
    SANDER, M
    BADER, FM
    GANTEN, D
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1993, 22 (07) : 364 - 368
  • [4] Differential development of early hypertension in heterozygous transgenic TGR(mREN2)27 rats
    Kreutz, R
    Fernandez-Alfonso, MS
    Paul, M
    Peters, J
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 1998, 20 (03) : 273 - 282
  • [5] REVERSAL OF THE SUPPRESSED KIDNEY RENIN LEVEL IN THE HYPERTENSIVE TRANSGENIC RAT TGR(MREN-2)27 BY ANGIOTENSIN-CONVERTING ENZYME-INHIBITION
    TOKITA, Y
    FRANCOSAENZ, R
    MULROW, PJ
    AMERICAN JOURNAL OF HYPERTENSION, 1995, 8 (10) : 1031 - 1039
  • [6] CHRONIC DEXAMETHASONE TREATMENT SUPPRESSES HYPERTENSION DEVELOPMENT IN THE TRANSGENIC RAT TGR(MREN2)27
    DJAVIDANI, B
    SANDER, M
    KREUTZ, R
    ZEH, K
    BADER, M
    MELLON, SH
    VECSEI, P
    PETERS, J
    GANTEN, D
    JOURNAL OF HYPERTENSION, 1995, 13 (06) : 637 - 645
  • [7] The hypertensive Ren-2 transgenic rat TGR(mREN2)27 in hypertension research - Characteristics and functional aspects
    Langheinrich, M
    Lee, MA
    Bohm, M
    Pinto, YM
    Ganten, D
    Paul, M
    AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (05) : 506 - 512
  • [8] Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27
    Lee, MA
    Bohm, M
    Paul, M
    Bader, M
    Ganten, U
    Ganten, D
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 270 (06): : E919 - E929
  • [9] Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2) 27 rats
    Jacke, K
    Witte, K
    Huser, L
    Behrends, S
    Lemmer, B
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 403 (1-2) : 27 - 35
  • [10] ENHANCED ALDOSTERONE BIOSYNTHESIS IN TGR(MREN2)27 - FUNCTIONAL-SIGNIFICANCE OF AN INTRAADRENAL RENIN-ANGIOTENSIN SYSTEM
    PETERS, J
    DJAVIDANI, B
    MUNTER, K
    BADER, M
    SANDER, M
    MULLINS, J
    GANTEN, D
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1992, 21 (11) : 545 - 546